{"organizations": [], "uuid": "042bc6a050cfcc6cbf17e354e656dbaadbe34273", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 1, "shares": 1, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biohaven-announces-robust-clinical/brief-biohaven-announces-robust-clinical-data-with-single-dose-rimegepant-that-defines-acute-and-durable-benefits-to-patients-idUSFWN1RX12L", "country": "US", "domain_rank": 408, "title": "BRIEF-Biohaven Announces Robust Clinical Data With Single Dose Rimegepant That Defines Acute And Durable Benefits To Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-23T05:08:00.000+03:00", "replies_count": 0, "uuid": "042bc6a050cfcc6cbf17e354e656dbaadbe34273"}, "author": "", "url": "https://www.reuters.com/article/brief-biohaven-announces-robust-clinical/brief-biohaven-announces-robust-clinical-data-with-single-dose-rimegepant-that-defines-acute-and-durable-benefits-to-patients-idUSFWN1RX12L", "ord_in_thread": 0, "title": "BRIEF-Biohaven Announces Robust Clinical Data With Single Dose Rimegepant That Defines Acute And Durable Benefits To Patients", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "biohaven pharmaceutical holding company ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 22 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:\n* BIOHAVEN ANNOUNCES ROBUST CLINICAL DATA WITH SINGLE DOSE RIMEGEPANT THAT DEFINES ACUTE AND DURABLE BENEFITS TO PATIENTS\n* BIOHAVEN PHARMACEUTICAL HOLDING SAYS BROAD AND CLINICALLY IMPORTANT BENEFITS BEYOND INITIAL REGISTRATIONAL ENDPOINTS ARE NOW REPORTED.\n* BIOHAVEN- RIMEGEPANT FIRST ORAL CGRP RECEPTOR ANTAGONIST TO DELIVER POSITIVE DATA ON PAIN FREEDOM IN TWO PIVOTAL PHASE 3 TRIALS IN ACUTE TREATMENT OF MIGRAINE Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-23T05:08:00.000+03:00", "crawled": "2018-04-23T05:26:09.043+03:00", "highlightTitle": ""}